Ftse Mib
33.986,47
0,73%
DAX
19.906,98
0,35%
S&P 500
5.952,71
-1,41%
NASDAQ
19.595,03
-2,12%
Bitcoin
94.477,15
-1,26%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Soligenix Inc (SNGX) Soligenix Inc (SNGX) Notizie

Soligenix Inc

SNGX
2,84
-0,05 (-1,73%)
Ultimo aggiornamento: 16:14:48
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
16/12/202413:30PRNUSSoligenix Initiates Confirmatory Phase 3 Clinical Trial of..
13/12/202423:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/12/202413:30PRNUSHyBryte™ Clinical Results Demonstrate Continued Improvement..
19/11/202413:30PRNUSSoligenix Announces Formation of European Medical Advisory..
14/11/202413:15PRNUSSoligenix Initiates a Phase 2 Clinical Trial of SGX945..
08/11/202422:14EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/11/202422:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/11/202422:10EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/11/202422:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202413:30PRNUSSoligenix Announces Recent Accomplishments And Third Quarter..
24/10/202413:30GLOBESoligenix, Inc. to Present at the 2024 ThinkEquity..
22/10/202413:30PRNUSSoligenix Receives Hong Kong Patent for Improved Production..
16/10/202413:30PRNUSSoligenix Invited to Present at Upcoming Investor..
11/10/202422:05EDGAR2Form 8-K - Current report
07/10/202413:30PRNUSHyBryte™ Expanded Treatment Results to be Presented at the..
03/10/202413:30PRNUSSoligenix Announces Partnership with Sterling Pharma..
16/9/202413:30PRNUSJoin Soligenix's Exclusive Live Investor Webinar and Q&A..
03/9/202413:30PRNUSSoligenix Receives European Patent for Improved Production..
16/8/202422:19EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16/8/202422:13EDGAR2Form 8-K - Current report
09/8/202422:09EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
09/8/202422:07EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
09/8/202422:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202413:30PRNUSSoligenix Announces Recent Accomplishments And Second..
05/8/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
01/8/202415:00GLOBEStrong Clinical Momentum for Soligenix's HyBryte™ in..
25/7/202413:30EDGAR2Form 8-K - Current report
15/7/202416:16GLOBEPRISM MarketView Features Q&A with Dr. Ellen Kim:..
09/7/202419:28EDGAR2Form 8-K - Current report
09/7/202413:30PRNUSExpanded HyBryte™ Treatment Demonstrating Positive Outcomes..
25/6/202413:30PRNUSSoligenix Announces Positive Clinical Results from a..
14/6/202413:30PRNUSA Comparison of Vaccine Technologies to be Presented at the..
05/6/202414:00GLOBESetting the Stage for Success: PRISM MarketView Highlights..
31/5/202414:00EDGAR2Form 8-K - Current report
31/5/202413:30PRNUSSoligenix Announces Reverse Stock Split
29/5/202422:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/5/202413:30PRNUSSoligenix Encourages Stockholders to Vote their Shares at..
28/5/202422:08EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
24/5/202422:05EDGAR2Form 8-K - Current report
24/5/202413:30PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
23/5/202413:30PRNUSSoligenix Encourages Stockholders to Vote "FOR" Reverse..
22/5/202422:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
21/5/202418:35GLOBEPRISM MarketView Highlights Soligenix, Inc. as it Builds on..
Apertura: 2,90 Min: 2,83 Max: 2,9728
Chiusura: 2,89

La tua Cronologia

NASDAQ
SNGX
Soligenix
BIT
P22462
NLBNPIT22462 20991231 41...
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network